Pharmabiz8m
CAGE Bio begins phase 2b clinical trial for CGB-500, a breakthrough topical JAK inhibitor for moderate to severe atopic dermatitis
CAGE Bio begins phase 2b clinical trial for CGB-500, a breakthrough topical JAK inhibitor for moderate to severe atopic dermatitis: San Carlos, California Saturday, January 11, 20 ...
Pharmabiz2h
Newron Pharma, Myung In Pharm ink license agreement to develop, manufacture & commercialize Newron’s evenamide in South Korea
Newron Pharma, Myung In Pharm ink license agreement to develop, manufacture & commercialize Newron’s evenamide in South Korea: Milan Saturday, January 11, 2025, 16:00 Hrs [IST] ...
Pharmabiz1h
FORE Biotherapeutics highlights pipeline achievements for its oncology programme; Provides objectives for 2025
FORE Biotherapeutics highlights pipeline achievements for its oncology programme; Provides objectives for 2025: Philadelphia Saturday, January 11, 2025, 17:00 Hrs [IST] FORE Bioth ...
Pharmabiz3h
SynCardia Systems gets CNIPA notification granting first patent covering company’s next-generation total artificial heart
SynCardia Systems gets CNIPA notification granting first patent covering company’s next-generation total artificial heart: Tucson, Arizona Saturday, January 11, 2025, 15:00 Hrs ...
Pharmabiz4h
Gaelic Labs establishes subsidiary in UAE, enabling access to growing Middle East pharma market
Gaelic Labs establishes subsidiary in UAE, enabling access to growing Middle East pharma market: Ireland Saturday, January 11, 2025, 13:30 Hrs [IST] Gaelic Laboratories, a Europea ...
Pharmabiz4h
Boehringer Ingelheim broadens oncology portfolio with license for Synaffix’s ADC technology
Boehringer Ingelheim broadens oncology portfolio with license for Synaffix’s ADC technology: Ingelheim Saturday, January 11, 2025, 14:00 Hrs [IST] Boehringer Ingelheim and Synaf ...
Pharmabiz5h
Seven research leaders awarded prestigious NIHR award
The NIHR has announced the latest outstanding researchers to become NIHR Research Professors. They will play a key role in undertaking professorial-level research that has a positive impact on the ...
Pharmabiz6h
US FDA grants priority review status to Johnson & Johnson’s nipocalimab BLA to treat generalized myasthenia gravis
US FDA grants priority review status to Johnson & Johnson’s nipocalimab BLA to treat generalized myasthenia gravis: Spring House, Pennsylvania Saturday, January 11, 2025, 12:00 ...
Pharmabiz4d
Indian healthcare sees medical networking as catalyst for quality services in remote regions
The Indian healthcare sector sees emergence of medical networking to revolutionise quality services in remote regions. This is despite the resource and infrastructural constraints leading to the ...
Pharmabiz4d
Santhera enters supply and distribution agreement with Clinigen Group for Agamree to treat patients with Duchenne muscular dystrophy
Santhera Pharmaceuticals announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of Agamree (vamorolone) in countries where the product is not ...
Pharmabiz7d
GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps
GSK plc announced that the China National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as an add-on therapy with ...
Pharmabiz5d
Parliamentary panel asks DoE to furnish justification on denying proposal for setting up of NIMERs
Expressing its concern over the Department of Expenditure's (DoE) decision to turn down the Department of Pharmaceuticals (DoP)’s proposal for setting up separate National Institutes for Medical ...